NEW YORK – In the days since the US Food and Drug Administration granted approval for Bristol Myers Squibb's nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for non-small cell lung cancer, the question as to where this new option fits into the lung cancer immunotherapy landscape has been top of mind for many oncologists.
Opdivo, Yervoy Another First-Line Option in NSCLC, Though Maybe Not Some Oncologists' Top Choice
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.